Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 4:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 102 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: solid to liquid Clear all
Terminated Phase 4 Interventional Results available

Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH)

NCT05228184
View directory record Official record
Conditions
Congenital Hypothyroidism
Interventions
Tirosint®-SOL, Levothyroxine Sodium
Drug
Lead sponsor
IBSA Institut Biochimique SA
Industry
Eligibility
1 Day to 9 Months
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 3, 2026, 4:56 PM EDT
Completed Early Phase 1 Interventional

Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases

NCT00424242
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Metastatic Cancer, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Pemetrexed
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Sep 3, 2026, 4:56 PM EDT
Terminated Phase 1Phase 2 Interventional

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

NCT01562899
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, BRAF Mutated Melanoma
Interventions
MEK162, AMG 479
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Sep 3, 2026, 4:56 PM EDT
Terminated Phase 1Phase 2 Interventional

A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors

NCT03592264
View directory record Official record
Conditions
Solid Tumor, Pancreatic Adenocarcinoma
Interventions
OBI-3424
Drug
Lead sponsor
OBI Pharma, Inc
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
5
States / cities
La Jolla, California • Los Angeles, California • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 3, 2026, 4:56 PM EDT
Completed Phase 1 Interventional

A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer

NCT03215511
View directory record Official record
Conditions
Solid Tumors Harboring NTRK Fusion
Interventions
Selitrectinib (BAY2731954)
Drug
Lead sponsor
Bayer
Industry
Eligibility
1 Month and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Sep 3, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)

NCT02559570
View directory record Official record
Conditions
Functional Constipation in Children Ages 6-17 Years
Interventions
Placebo, LIN Dose A, LIN Dose B, LIN Dose C, LIN 145 µg
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 17 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
60
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 51 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Sep 3, 2026, 4:56 PM EDT
Completed Phase 1 Interventional

A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer

NCT02122913
View directory record Official record
Conditions
Solid Tumors Harboring NTRK Fusion
Interventions
Larotrectinib (Vitrakvi, BAY2757556)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
8
States / cities
Aurora, Colorado • Boston, Massachusetts • Cleveland, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 3, 2026, 4:56 PM EDT
Active, not recruiting Phase 2 Interventional

High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients

NCT04613206
View directory record Official record
Conditions
Immunization; Infection, Transplantation Infection, Influenza, Solid Organ Transplant
Interventions
High Dose Quadrivalent Inactivated Influenza Vaccine, Standard Dose Quadrivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 3, 2026, 4:56 PM EDT
Completed Phase 2 Interventional

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

NCT02576431
View directory record Official record
Conditions
Solid Tumors Harboring NTRK Fusion
Interventions
BAY2757556 (Larotrectinib, Vitrakvi)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
18
States / cities
Palo Alto, California • Santa Monica, California • Pembroke Pines, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 3, 2026, 4:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Amitiza® Plus GoLYTELY® (PEG) Versus Placebo Plus GoLYTELY® for Outpatient Colonoscopy Preparation

NCT00645801
View directory record Official record
Conditions
Colonoscopy
Interventions
lubiprostone (Amitiza), Placebo
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
3
States / cities
Detroit, Michigan • Novi, Michigan • West Bloomfield, Michigan
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Sep 3, 2026, 4:56 PM EDT
Completed Not applicable Interventional

Randomized Controlled Trial of Vaginal Cryotherapy for Pelvic Floor Myofascial Pain

NCT03885791
View directory record Official record
Conditions
Pelvic Floor Myofascial Pain, Pelvic Pain, Myofascial Pain
Interventions
vaginal cryotherapy
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 3, 2026, 4:56 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)

NCT06347159
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
EDG-7500
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
21
States / cities
San Francisco, California • Stanford, California • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 3, 2026, 4:56 PM EDT
Completed Phase 1Phase 2 Interventional

A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors

NCT00841191
View directory record Official record
Conditions
Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms
Interventions
CNTO 328; Anti-interleukin-6 monoclonal antibody
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Sep 3, 2026, 4:56 PM EDT
Completed No phase listed Observational

Gastrointestinal Dysfunction in Children Affected With Mitochondrial Disorders

NCT01137240
View directory record Official record
Conditions
Gastrointestinal Dysfunction, Mitochondrial Disorders
Interventions
gastric emptying scan
Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
3 Years to 18 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2012 · Synced Sep 3, 2026, 4:56 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of Acute Topical and Aromatic Essential Oil-Based Products for Cognitive Support

NCT07623811
View directory record Official record
Conditions
Healthy
Interventions
Placebo, Cognitive Support System
Other
Lead sponsor
dōTERRA International
Industry
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Pleasant Grove, Utah
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 3, 2026, 4:56 PM EDT
Completed Phase 1 Interventional

Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A in Treating Patients With Advanced Solid Tumors

NCT00645060
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
high performance liquid chromatography, pharmacological study, radionuclide imaging, single photon emission computed tomography, yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A
Other · Procedure · Radiation
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Sep 3, 2026, 4:56 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors

NCT04084366
View directory record Official record
Conditions
Locally Advanced Solid Tumor
Interventions
OBI-999
Drug
Lead sponsor
OBI Pharma, Inc
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
La Jolla, California • New York, New York • Germantown, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Sep 3, 2026, 4:56 PM EDT
Recruiting No phase listed Observational

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

NCT05868629
View directory record Official record
Conditions
Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
Interventions
Non-investigational
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 100 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
Torrance, California • Denver, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 3, 2026, 4:56 PM EDT
Completed No phase listed Observational

Circulating Tumor DNA As Liquid Biopsy in Patients with Stage IV Solid Tumors, a Feasibility Study At MUSC HCC

NCT03302325
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
research blood draws
Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 3, 2026, 4:56 PM EDT
Completed Not applicable Interventional

Peroral Endoscopic Myotomy (POEM) for Esophageal Motility

NCT02314741
View directory record Official record
Conditions
Achalasia
Interventions
POEM Procedure
Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 18, 2018 · Synced Sep 3, 2026, 4:56 PM EDT
Active, not recruiting Phase 1 Interventional

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

NCT03821935
View directory record Official record
Conditions
Advanced Solid Tumors Cancer
Interventions
Livmoniplimab, Budigalimab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
21
States / cities
Springdale, Arkansas • Duarte, California • Irvine, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 3, 2026, 4:56 PM EDT
Terminated Phase 1 Interventional

A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors.

NCT01286974
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
[14C]linifanib, ABT-869, linifanib
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 20, 2012 · Synced Sep 3, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance

NCT02286921
View directory record Official record
Conditions
Castration Resistant Metastatic Prostate Cancer
Interventions
Testosterone cypionate, Enzalutamide, Testosterone Enanthate
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 80 Years · Male only
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
17
States / cities
Birmingham, Alabama • Duarte, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Sep 3, 2026, 4:56 PM EDT
Not yet recruiting Phase 2 Interventional

BRain-AVOidant Proton Craniospinal Irradiation for Leptomeningeal Metastases From Solid Tumor Malignancies

NCT07789912
View directory record Official record
Conditions
Leptomeningeal Metastasis, Breast Cancer, Lung Cancer (NSCLC)
Interventions
Radiation Treatments Using Brain- Avoidant Proton Craniospinal Irradiation (BRAVO- pCSI)
Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 3, 2026, 4:56 PM EDT